• Live Coronavirus, Spain, today

  • Interview "Our vaccine has shown high efficacy also against the Brazilian and South African variants"

The Minister of Health, Carolina Darias, announced this weekend that on Tuesday, April 13, the first doses of the

vaccine from

Janssen

, a subsidiary of the American Johnson & Johnson,

will arrive in Spain

, which only requires one dose for its administration.

The forecast of the Ministry of Health is that

Spain will receive up to 5.5 million vials of Janssen between April and June

.

"These vaccines arrive early Tuesday morning and in principle they will be applied according to the latest update of the vaccination strategy in the same typology as those of RNA [Pfizer and Moderna]; that is, we will be converging for 80 years down, "said the minister in Las Palmas de Gran Canaria, reports Europa Press.

What is the Janssen vaccine like?

Named Ad26.COV2-S, it is a vaccine

based on a viral vector without replication capacity,

a human adenovirus (type 26), which encodes the SARS-CoV-2 spike glycoprotein and is capable of

awakening

the system. immune to recognize and attack the pathogen.

The vaccine has been developed from

the company's

AdVac technology platform

, a tool that had already been used to develop the Ebola vaccine, among others.

What are your strengths?

First, with the Janssen vaccine, only one dose is necessary to achieve immunization.

(Both the Pfizer, Moderna and AstraZeneca vaccines require the administration of two doses separated in time).

In addition, another of its advantages is its stability at refrigeration temperatures.

It can be kept for three months at a temperature between 2 and 8 degrees (in a conventional refrigerator)

and up to two years at -20 degrees.

"It is compatible with our usual supply chains for other drugs. It does not require specific refrigeration systems for its distribution,"

Hanneke Schuitemaker, global head of Viral Vaccines at Janssen,

told this newspaper a few weeks ago

.

What is its effectiveness?

The European Union gave the green light to Janssen's vaccine on March 11.

The product thus became the fourth approved vaccine against Covid in the EU.

For the go-ahead, the European Medicines Agency had data from a study conducted in more than 44,000 people that showed a 67% reduction in the number of symptomatic cases within two weeks of receiving the vaccine (effectiveness reached 86 % with respect to severe cases and hospitalizations).

The ENSAMBLE trial, still ongoing and in which several Spanish hospitals, has taken into account, with good data, the usefulness of the vaccine against the variants of the virus that have been appearing, such as the South African or the Brazilian.

The company has also launched the necessary clinical trials to demonstrate the effectiveness of the vaccine in children and adolescents.

On the other hand, the multinational company also continues to carry out trials with other administration guidelines,

testing vaccination with two doses to see if it improves

the efficacy

even more

, and will have conclusions from these analyzes later in the year.


How many vaccines will arrive?

The company has reached an agreement with the European Union to supply up to 200 million doses throughout this year.


European Union, with which the company has the commitment to supply up to

200 million doses throughout this year.

Last Monday, the Minister of Health, Carolina Darias, announced that in the first shipments about

300,000 doses

would be received

.

According to his words, between April and June, Spain will have

5.5 million vials of the Janssen vaccine

.

Since the start of the vaccination campaign, last December, Spain has supplied around 10 million vaccines (with the formulations of Pfizer, Moderna and AstraZeneca).

How will the Janssen vaccine be administered?

Although many details have not yet been given, the Minister of Health, Carolina Darias, advanced in her last appearance that the Janssen vaccine "in principle will be applied according to the latest update of the vaccination strategy, in the same typology than those of RNA [Pfizer and Moderna]; that is, we will be converging from 80 years on down ".

What are your risks?

The

most common side effects described

(may affect 1 in 10 patients according to the package insert) were headache, nausea, muscle aches, pain at the injection site and feeling very tired.

Last Friday, the European Medicines Agency (EMA) announced that it is investigating the risk of developing thromboembolisms with the Janssen Covid-19 vaccine after receiving a "safety signal" related to

four serious cases of blood clotting after the vaccination

with this preparation.


According to the criteria of The Trust Project

Know more

  • Science and Health

  • Coronavirus

  • Vaccines

  • Covid 19

CoronavirusAstraZeneca reduces the effectiveness of its vaccine against Covid-19 to 76% after updating its data

CoronavirusAstraZeneca Vaccine: Why It Has Been Discontinued and What Will Happen From Now

Coronavirus Health lists the antecedents of 'alarm' to consider when vaccinating with AstraZeneca

See links of interest

  • Work calendar

  • Rocio Carrasco

  • Home THE WORLD TODAY

  • Internazionale - Cagliari

  • Burnley - Newcastle United

  • Villarreal - Osasuna

  • Malaga - Albacete

  • Betis - Atlético, live